ACP
FBRX icon

Acuta Capital Partners’s Forte Biosciences FBRX Stock Holding History

Acuta Capital Partners’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,469
Closed -$143K – 31
2025
Q1 		$143K Buy
18,469
+330
+2% +$3.9K 0.17% 31
2024
Q4 		$412K Buy
+18,139
New +$216K 0.41% 35
2017
Q4 		– Sell
-670
Closed -$3.13M – 80
2017
Q3 		$3.13M Buy
+670
New +$2.98M 0.56% 32

Other funds holding FBRX

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Acuta Capital Partners's FBRX Position: Q2 2025 in Review

Acuta Capital Partners sold out of Forte Biosciences (FBRX) in Q2 2025, closing a stake of 18,469 shares — an estimated $143K sold.

Acuta Capital Partners first reported a position in FBRX in Q3 2017 and held it in 3 quarters. The position peaked at $3.13M in Q3 2017. 33 funds tracked by Wall St. Rank hold FBRX as of Q2 2025.

  • Acuta Capital Partners reported no remaining Forte Biosciences position as of Q2 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 18,469 Forte Biosciences shares in Q2 2025, an estimated $143K.
  • Acuta Capital Partners first reported a position in Forte Biosciences in Q3 2017 and held it in 3 quarters.
  • Acuta Capital Partners's Forte Biosciences position peaked at $3.13M in Q3 2017.
  • 33 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2025.

Based on Acuta Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.